Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study.
COVID-19
Healthcare workers
Re-infection
Surveillance
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
14 10 2021
14 10 2021
Historique:
received:
23
06
2021
accepted:
27
09
2021
entrez:
15
10
2021
pubmed:
16
10
2021
medline:
21
10
2021
Statut:
epublish
Résumé
In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 infection according to baseline serostatus. Baseline serologies were performed among HCW from 23 Swiss healthcare institutions between June and September 2020, before the second COVID-19 wave. Participants answered weekly electronic questionnaires covering information about nasopharyngeal swabs (PCR/rapid antigen tests) and symptoms compatible with coronavirus disease 2019 (COVID-19). Screening of symptomatic staff by nasopharyngeal swabs was routinely performed in participating facilities. We compared numbers of positive nasopharyngeal tests and occurrence of COVID-19 symptoms between HCW with and without anti-nucleocapsid antibodies. A total of 4812 HCW participated, wherein 144 (3%) were seropositive at baseline. We analyzed 107,807 questionnaires with a median follow-up of 7.9 months. Median number of answered questionnaires was similar (24 vs. 23 per person, P = 0.83) between those with and without positive baseline serology. Among 2712 HCW with ≥ 1 SARS-CoV-2 test during follow-up, 3/67 (4.5%) seropositive individuals reported a positive result (one of whom asymptomatic), compared to 547/2645 (20.7%) seronegative participants, 12 of whom asymptomatic (risk ratio [RR] 0.22; 95% confidence interval [CI] 0.07 to 0.66). Seropositive HCWs less frequently reported impaired olfaction/taste (6/144, 4.2% vs. 588/4674, 12.6%, RR 0.33, 95% CI 0.15-0.73), chills (19/144, 13.2% vs. 1040/4674, 22.3%, RR 0.59, 95% CI 0.39-0.90), and limb/muscle pain (28/144, 19.4% vs. 1335/4674, 28.6%, RR 0.68 95% CI 0.49-0.95). Impaired olfaction/taste and limb/muscle pain also discriminated best between positive and negative SARS-CoV-2 results. Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least 8 months.
Sections du résumé
BACKGROUND
In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 infection according to baseline serostatus.
METHODS
Baseline serologies were performed among HCW from 23 Swiss healthcare institutions between June and September 2020, before the second COVID-19 wave. Participants answered weekly electronic questionnaires covering information about nasopharyngeal swabs (PCR/rapid antigen tests) and symptoms compatible with coronavirus disease 2019 (COVID-19). Screening of symptomatic staff by nasopharyngeal swabs was routinely performed in participating facilities. We compared numbers of positive nasopharyngeal tests and occurrence of COVID-19 symptoms between HCW with and without anti-nucleocapsid antibodies.
RESULTS
A total of 4812 HCW participated, wherein 144 (3%) were seropositive at baseline. We analyzed 107,807 questionnaires with a median follow-up of 7.9 months. Median number of answered questionnaires was similar (24 vs. 23 per person, P = 0.83) between those with and without positive baseline serology. Among 2712 HCW with ≥ 1 SARS-CoV-2 test during follow-up, 3/67 (4.5%) seropositive individuals reported a positive result (one of whom asymptomatic), compared to 547/2645 (20.7%) seronegative participants, 12 of whom asymptomatic (risk ratio [RR] 0.22; 95% confidence interval [CI] 0.07 to 0.66). Seropositive HCWs less frequently reported impaired olfaction/taste (6/144, 4.2% vs. 588/4674, 12.6%, RR 0.33, 95% CI 0.15-0.73), chills (19/144, 13.2% vs. 1040/4674, 22.3%, RR 0.59, 95% CI 0.39-0.90), and limb/muscle pain (28/144, 19.4% vs. 1335/4674, 28.6%, RR 0.68 95% CI 0.49-0.95). Impaired olfaction/taste and limb/muscle pain also discriminated best between positive and negative SARS-CoV-2 results.
CONCLUSIONS
Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least 8 months.
Identifiants
pubmed: 34649585
doi: 10.1186/s12916-021-02144-9
pii: 10.1186/s12916-021-02144-9
pmc: PMC8514323
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
270Subventions
Organisme : schweizerischer nationalfonds zur förderung der wissenschaftlichen forschung
ID : 31CA30_196544
Organisme : schweizerischer nationalfonds zur förderung der wissenschaftlichen forschung
ID : PZ00P3_179919
Organisme : federal office of public health switzerland
ID : 20.008218/421-28/1
Informations de copyright
© 2021. The Author(s).
Références
Nat Commun. 2021 Mar 19;12(1):1724
pubmed: 33741972
Clin Infect Dis. 2021 May 16;:
pubmed: 33993225
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Clin Microbiol Infect. 2021 Sep;27(9):1336-1344
pubmed: 34020033
Crit Care. 2020 Jul 13;24(1):421
pubmed: 32660520
Clin Infect Dis. 2021 May 27;:
pubmed: 34043763
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Lancet Respir Med. 2021 Jul;9(7):712-720
pubmed: 33865504
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
BMJ. 2020 May 21;369:m2066
pubmed: 32439655
J Infect. 2021 May;82(5):162-169
pubmed: 33766553
Clin Microbiol Infect. 2020 Nov;26(11):1557.e1-1557.e7
pubmed: 32745595
Med Mal Infect. 2020 Aug;50(5):436-439
pubmed: 32305563
Clin Infect Dis. 2021 Jan 09;:
pubmed: 33421056
Clin Infect Dis. 2020 Aug 25;:
pubmed: 32840608
Nat Rev Immunol. 2021 Jun;21(6):395-404
pubmed: 33927374
J Infect. 2021 Aug;83(2):237-279
pubmed: 34052242
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
EClinicalMedicine. 2021 May;35:100861
pubmed: 33937733
JAMA Intern Med. 2021 May 1;181(5):672-679
pubmed: 33625463
Clin Infect Dis. 2021 Jan 02;:
pubmed: 33386403
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246